Multiparametric prognostic evaluation of biological factors in primary breast cancer

Journal of the National Cancer Institute

Volumn 84, Issue 16, 1992, Pages 1266-1272

  Spyratos, Frédérique ^a   Martin, Pierre Marie ^c   Hacène, Kamel ^a   Romain, Sylvie ^c   Andrieu, Catherine ^a   Ferrero poüs, Magali ^a   Deytieux, Stéphanie ^a   Doussal, Viviane Le ^a   Tubiana hulin, Michéle ^b   Brunet, Maurice ^a  

^a Centre René Huguelin   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; CATHEPSIN D; PROUROKINASE; THYMIDINE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN D; CELL DIVISION; CHI-SQUARE DISTRIBUTION; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHATIC METASTASIS; MIDDLE AGE; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; URINARY PLASMINOGEN ACTIVATOR;

EID: 0026779790     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.16.1266     Document Type: Article

References (47)

1. Merkel, D E, Osborne C K: Prognostic factors in breast cancer. Hematol Oncol Clin North Am 3:641-652, 1989
2. Sunderland M C, McGuire W L: Prognostic indicators in invasive breast cancer. Surg Clin North Am 2:989-1004, 1990
3. McGuire W L: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5:428-433, 1978
4. Beerman H, Kluin P M, Hermans J, et al: Prognostic significance of DNA-ploidy in a series of 690 primary breast cancer patients. Int J Cancer 45:34-39, 1990
5. Merkel D E, McGuire W L: Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer 65:1194-1205, 1990
6. Thorpe S M, Rochefort H, Garcia M, et al: Association between high concentrations of Mr 52, 000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008-6014, 1989
7. Tandon A K, Clark G M, Chamness G C, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297-302, 1990
8. Duffy M J, Reilly D, O’Sullivan C, et al: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829, 1990
9. Foekens J A, Rio M C, Seguin P, et al: Prediction of relapse and survival in breast cancerpatients by pS2 protein status. Cancer Res 50:3832-3837, 1990
10. Sainsbury JR, Farndon JR, Needham GK, et AL: Epidermal-growth-factor receptor status as predictor of early recurrence and of death from breast cancer. Lancet 1:1398-1402, 1987
11. Grimaux M, Romain S, Remvikos Y, et al: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77-90, 1989
12. Spyratos F, Delarue JC, Andrieu C, et al: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83-89, 1990
13. Callahan R, Campbell G: Mutations in human breast cancer: An overview. J Natl Cancer Inst 81:1780-1786, 1989
14. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957
15. Scarff RW, Torloni H: Histological typing of breast tumors. Geneva: World Health Organization, 13-20, 1968
16. European Organization for Research and Treatment of Cancer (EORTC): Breast cancer cooperative group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16:1513-1515, 1980
17. Thorpe SM, Koenders A: Standardization of steroid receptor assays in human breast cancer. III. Selection of reference material for intra- and interlaboratory quality control. Eur J Cancer Clin Oncol 22:939-944, 1986
18. Spyratos F, Briffod M, Gentile A, et al: Flow cytometric study of DNA distribution in cytopunctures of benign and malignant breast lesions. Anal Quant Cytol Histol 9:485-494, 1987
19. Wafflart J, Daver A, Grenier J, et al: Cytosolic thymidine kinase activity as a marker of cell proliferation in primary breast cancer. Breast Cancer Res Treat 14:35, 1989
20. Hartigan JA: Clustering Algorithms. New York: John Wiley & Sons, 1975
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
23. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
24. Kalbfleish B: Some extensions and applications of Cox’s regression and life model. Spring Meetings of the Biometrics Society. Florida State University. Tallahassee, Fla, March 22-26, 1974
25. Altshuler B: Theory for the measurement of competing risks in animal experiments. Math Biosci 6:1-11, 1970
26. Martin PM, Rolland PH, Jacquemier J, et al: Multiple steroid receptors in human breast cancer. III. Relationships between steroid receptors and the state of differentiation and the activity of carcinomas throughout the pathologic features. Cancer Chemother Pharmacol 2:115-120, 1979
27. Levine MN, Browman GP, Gent M, et al: When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 9:348-356, 1991
28. Spyratos F, HacEne K, Tubiana-Hulin M, et al: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol 25:1233-1240, 1989
29. Moon TE, Jones SE, Bonadonna G, et al: Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 10:396-403, 1987
30. Foucre D, Bouchet C, Oglobine J, et al: Concentration of cathepsin-D, urokinase activators and inhibitors in malignant versus benign breast tumors: Possible role in tumour invasion. Br J Cancer 64:926-932, 1991
31. Romain S, Javre JL, Samperez S, et al: Prognostic value of thymidine kinase in cancer of the breast. Bull Cancer 77:973-983, 1990
32. Fisher ER: Prognostic and therapeutic significance of pathological features of breast cancer. NCI Monogr 1:29-34, 1986
33. Contesso G, Mouriesse H, Friedman S, et al: The importance of histologic grade in long-term prognosis of breast cancer: A study of 1010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5:1378-1386, 1987
34. Le Doussal V, Tubiana-Hulin M, Friedman S, et al: Prognostic value of histologic grade nuclear components of Scarff-Bloom- Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:1914-1921, 1989
35. Duffy MJ, Brouillet JP, Reilly D, et al: Cathepsin D concentration in breast cancer cytosols: Correlation with biochemical, histological and clinical findings. Clin Chem 37:101-104, 1991
36. Romain S, Muracciole X, Varette 1, et al: Cathepsin D: An independent prognostic factor in cancer of the breast. Bull Cancer 77:439-447, 1990
37. Zucker S: A critical appraisal of the role of proteolytic enzymes in cancer invasion: Emphasis on tumor surface proteinases. Cancer Invest 6:219-231, 1988
38. McDonnell S, Matrisian LM: Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev 9:305-319, 1990
39. Baker MS, Bleakley P, Woodrow GC, ET al: Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 50:4676-4684, 1990
40. Silvestrini R, Daidone MG, Valagussa P, ET al: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165-1171, 1989
41. Clark GM, Dressler LG, Owens MA, ET al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
42. Peto R: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials along 28, 896 women. N Engl J Med 319:1681-1692, 1988
43. Mittra I: Has adjuvant treatment of breast cancer had an unfair trial? Br Med J 301:1317-1319, 1990
44. Mittra I, MacRae KD: A meta-analysis of reported correlations between prognostic factors in breast cancer: Does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 27:1574-1583, 1991
45. Schmitt M, Janicke F, Graeff H: Tumor associated fibrinolysis: The prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1:695-702, 1990
46. Janicke F, Schmitt M, Ulm K, et al: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2:1049, 1989
47. Grondahl-Hansen J, Rosenquist C, Thorpe S: ELISA for the measurement of urokinasetype plasminogen activator in breast cancer cytosols. Cell surface properties and tumor- specific antigens: Role in metastasis and host immune response. In Proceedings of the Second Workshop of the European Concerted Action. Munich, January 25-26, 1991